Company: STAA
Filing Date: 2025-09-24
Form Type: DEFC14A
Source: 0001213900-25-090869
Chunk: 5

Company: STAAR SURGICAL CO
Filing Date: 2025-09-24
Form: DEFC14A
Chunk 5
---
 stockholders approve the Merger Agreement Proposal. For the reasons discussed in this Proxy Statement, we OPPOSEthe Proposed Merger and the approval of the Merger Agreement Proposal. To that end, we are soliciting your proxy to vote “AGAINST”
the Merger Agreement Proposal.

We
recommend that you demonstrate your opposition to the Merger Agreement Proposal and send a message to the Board that the Merger Agreement
Proposal is NOTin the best interests of stockholders by using the enclosed GREEN Proxy
Card to vote via the Internet or by telephone today. Alternatively, you may complete, sign, date and promptly return the enclosed GREENProxy Card in the postage-paid envelope provided.

If you have
any questions or require any assistance with voting your shares, please contact our proxy solicitor, Saratoga, by calling (212) 257-1311
or toll free at (888) 368-0379, or by email at info@saratogaproxy.com.

<div align='center'>REASONS TO VOTE “ AGAINST” THE MERGER AGREEMENT PROPOSAL</div>

Broadwood
has been a committed investor in, and strong supporter of, STAAR for more than thirty years. We have provided capital to the Company on
various occasions and have purchased a substantial number of additional shares as recently as a few months ago. Today, we beneficially
own approximately 27.5% of STAAR’s outstanding shares, making us the Company’s largest stockholder by a significant margin.

We initially
invested in STAAR more than three decades ago, and have added to our position over time, because we strongly believe in the Company’s
ability to create substantial long-term value for stockholders. We believe STAAR’s superior and proprietary technology, as well
as its global scale, position the Company to take a significant portion of the refractive surgery market, become a highly profitable enterprise
and, ultimately, deliver upon its vision to be the first choice for surgeons and patients seeking visual freedom from glasses and contact
lenses.

We
share management’s view that the Company’s near-term challenges with respect to inventory, tariffs, and other issues are
transitory,1 and we regard them as unlikely to materially diminish the long-term value
of the business. In fact, we believe that those challenges have already been substantially resolved2
and that the Company is poised to return to growth and achieve sustained profitability. Furthermore, recent clinical data indicate that
the advantages of STAAR’s technology over